Vium Biosciences Secures Over RMB 100 Million in Series D2+ Financing to Accelerate Ophthalmic Innovative Drug Pipeline

Jul 21, 2025 14:23 CST Updated 14:23

VIVAVISION

Innovative Drug Developer

▲ The 14th issue of Gao特佳's industry research journal, "Gao·Insights," has been officially released. The core research report focuses on AI-driven drug discovery, providing an in-depth analysis of the application potential of AI technology across all stages of drug development to shorten R&D cycles, reduce costs, and improve success rates.

Recently, VIVAVISION announced the successful completion of over RMB 100 million in D2+ round financing.WorkAs a biotechnology company that has always been deeply engaged in the ophthalmology field, VIVAVISION's fundraising will mainly be used to accelerate the advancement of late-stage clinical trials for several core pipelines, support preclinical pipeline research and development, and expand and upgrade the technological innovation platform to continuously enhance R&D efficiency and capabilities. April 2021,VIVAVISION Announces Completion of 300 Million RMB Financing, Gao Te Jia Participates in Investment.

The company's core pipeline has currently concentrated into the middle and late stages of clinical trials, with frequent good news recently:VVN461LDReceived positive initial written feedback from the FDA, requiring only the completion of a single Phase III pivotal clinical study for treating post-operative ocular inflammation to file an NDA;VVN461HDIn China, it has been included in the "Breakthrough Therapy List" by the National Medical Products Administration (NMPA), with the potential to receive expedited review and approval in subsequent processes.VVN001As a new generation of domestically produced dry eye drops, its Phase III clinical trial is proceeding steadily;VVN1901The first patient has recently been successfully enrolled in the Phase II clinical trial for the treatment of neurotrophic keratitis, officially entering the critical clinical stage.

Dr. Shen Wang, founder and CEO of VIVAVISION, stated:"We sincerely thank the strong support from this round of investors and the long-term trust from our existing shareholders, which is a solid driving force for the company's continuous development. It also strengthens our belief to fully accelerate the commercial cooperation of mid-to-late stage pipelines and the forward-looking layout of industrialization. VIVAVISION has always been deeply engaged in the ophthalmology field, adhering to the path of independent innovation. Relying on the advantages of its own technology platform, we will proceed steadily and continue to innovate. Our goal is to achieve China-produced breakthroughs in ‘First-in-Class’ (first of its kind) and ‘Best-in-Class’ (best of its kind) ophthalmic drugs, and ultimately grow into a benchmark enterprise in the ophthalmology field, based in China while benefiting patients worldwide."

About Gortec Investment

GaoTeJia Investment was founded in Shenzhen in 2001, being the first in the industry to propose the investment model of "thematic industry investment," focusing on healthcare industry investments. It is led by strategic equity investments and covers all investment stages, including VC, PE, Pre-IPO, and M&A. With one of the few professional investment teams in China that deeply focuses on the healthcare track, it builds an investment ecosystem platform for the healthcare industry and aims to become a healthcare investment institution with global influence.

Gortka Investment's asset management scale exceeds 23 billion RMB, with 35 healthcare industry funds. It has invested in over 110 healthcare companies and facilitated the successful listing of 38 enterprises, including Mindray Medical, United Imaging Healthcare, and Akeso Biopharma. Gortka Investment operates in China and globally, establishing operational centers in Shenzhen, Shanghai, Beijing, Hong Kong, and other locations. It is committed to investing in outstanding healthcare companies worldwide, creating new development opportunities for global capital and medical enterprises, and assisting entrepreneurs in building great companies.